Blomquist & Associates was founded during 2001. We have advised private equity investors, as well as business executives in the pharma, biotech, diagnostics, medical device, Health IT and nutraceutical industries on over 90 projects. Our project experience ranges from investment due diligence, to IP licensing, and asset acquisition.
We have a breadth and depth of expertise in a broad range of diseases and therapeutic areas, such as cancer, inflammatory diseases, multiple sclerosis, diabetes and obesity, anti-infectives (e.g. HIV anti-retroviral therapies, HCV anti-viral therapies), vaccines, retinal diseases and inherited diseases.
Our Philosophy The best advice and insights have a foundation in facts and evidence, and is a result of critical, systematic analysis and objective synthesis. We follow our philosophy, so you can have confidence in our conclusions and advice. Further, we believe in using a hypothesis-driven scientific method when conducting our work. Hence, we also seek contradictory evidence that could disprove our initial belief or hypothesis and shift our perspective. Our experience tells us that weighing evidence for a position contrary to our initial belief is hard intellectual work. We devote the time and energy needed, and have the intellectual confidence to do so. We believe when we look at evidence without needing to prove ourselves right, we find evidence that helps us create an even better result. If we don’t find any evidence that contradicts our initial hypothesis, then we believe we have a reasonable chance we’re on the right path.
We have learned to not get caught up in the spell or allure of an exciting new technology, novel drug or innovative device, and apply the right degree of skepticism in our work. We strive to follow proper business discipline with careful, objective reasoning without confirmation bias when conducting due diligence.
We have the passion, drive and experience to undertake tough challenges, and deliver the best result possible.